newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company's